Development of a potent Zika virus vaccine using self-amplifying messenger RNA

Citations Over TimeTop 10% of 2020 papers

Abstract

Zika virus (ZIKV) is the cause of a pandemic associated with microcephaly in newborns and Guillain-Barre syndrome in adults. Currently, there are no available treatments or vaccines for ZIKV, and the development of a safe and effective vaccine is a high priority for many global health organizations. We describe the development of ZIKV vaccine candidates using the self-amplifying messenger RNA (SAM) platform technology delivered by cationic nanoemulsion (CNE) that allows bedside mixing and is particularly useful for rapid responses to pandemic outbreaks. Two immunizations of either of the two lead SAM (CNE) vaccine candidates elicited potent neutralizing antibody responses to ZIKV in mice and nonhuman primates. Both SAM (CNE) vaccines protected these animals from ZIKV challenge, with one candidate providing complete protection against ZIKV infection in nonhuman primates. The data provide a preclinical proof of concept that a SAM (CNE) vaccine candidate can rapidly elicit protective immunity against ZIKV.

Related Papers

• → A Biomimetic Nanodecoy Traps Zika Virus To Prevent Viral Infection and Fetal Microcephaly Development(2018)80 cited
• → Zika virus and the nonmicrocephalic fetus: why we should still worry(2018)66 cited
• → Risks of Zika virus during the first trimester of pregnancy(2016)14 cited
• → Laboratory Evaluation of Infants with Possible Congenital Zika Virus Infection(2017)1 cited
• Microcephaly in Zika Virus Infection.(2017)